HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

INMD

InMode Ltd. (NASDAQ)

Healthcare — Medical Devices

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. The company also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. In addition, it offers hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. The company was incorporated in 2008 and is headquartered in Yokne'am, Israel.

Hold 3.0 / 5 3 analysts
$14.68
+$0.06 (+0.41%)
Target: $14.33 (-2.4%)
Sign in to add INMD to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$843.82M
P/E Ratio (TTM)10.87
Forward P/E10.10
EPS (TTM)$1.35
Dividend Yield-
Profit Margin23.27%
Revenue Growth5.30%
ROE13.62%
Debt/Equity0.73
Recommendation Hold 3.0
Analyst Target$14.33
Analysts3
Indexes NASDAQ

Technical Indicators

RSI (14)72.5
Beta1.93
SMA 20-
SMA 40-
52-Week High$16.74
52-Week Low$12.72
50-Day Avg$13.96
200-Day Avg$14.35
Avg Volume835.6K
Volume511.2K

Performance Analysis

NEUTRAL

INMD presents a mixed picture with both positive and negative indicators.

~ Trading at 49% of its 52-week range.
- RSI at 72.5 indicates overbought conditions — a pullback may be due.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
+ P/E of 10.9 suggests the stock may be undervalued.
~ Modest revenue growth of 5.3% year-over-year.
+ Healthy profit margin of 23.3%.
~ Wall Street consensus is "Hold" from 3 analysts.
- Average analyst target of $14.33 implies 2.4% downside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:15 UTC

Back to Screener Export Report